ADAMTS1

Across TCGA pan-cancer cohorts, ADAMTS1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ADAMTS1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher ADAMTS1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADAMTS1 expression acts as an unfavorable survival marker.

DLBC, LAML, and READ are the cancer types where ADAMTS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
LAML	DFS	Median	All	0.165	0.581	.034	12	view →
READ	OS	Median	II,III,IV	0.187	0.653	.030	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
GBM	DFS	Median	All	0.064	0.242	.032	3	view →
LIHC	OS	Median	II,III,IV	0.248	0.715	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ADAMTS1–DLBC (DFS)

Open the DLBC breakdown →